Hypothesis

Aging shifts cfDNA toward longer, hypomethylated fragments that act as potent TLR9 ligands, creating a feed‑forward loop that amplifies inflamm‑aging.

Mechanistic reasoning

1. Methylation governs nuclease access – Low CpG methylation increases DNASE1L3 cutting efficiency, altering fragment size and end motifs [5]. In older plasma, global hypomethylation at ~2 000 age‑related DMCs [1] therefore favors generation of longer cfDNA pieces.
2. Chromatin remodeling enlarges protected fragments – Nucleosome repeat length (NRL) rises with age, moving signals from heterochromatin to euchromatin [4]. Euchromatin is less methylated and more accessible, so the nuclease‑protected DNA surrounding these nucleosomes retains hypomethylated CpGs.
3. Size‑selected fragments retain immunostimulatory motifs – cfDNA fragments >175 bp, enriched in elderly samples [3], are sufficient to contain multiple CpG dinucleotides. Hypomethylated CpGs within these fragments are optimal TLR9 agonists, whereas methylated CpGs blunt signaling.
4. TLR9 signaling fuels inflamm‑aging – Plasma cfDNA activates TLR9 on monocytes and macrophages, driving NF‑κB–dependent transcription of MCP‑1, IL‑6 and other inflamm‑aging mediators [2]. The observed correlation between hypomethylation and elevated MCP‑1 may thus reflect direct TLR9 stimulation rather than a passive biomarker.

Testable predictions

• Prediction 1: Size‑fractionated cfDNA from individuals >65 yr will show a higher proportion of hypomethylated CpGs in the >175 bp fraction compared with <175 bp fractions, whereas

Hypothesis

Intermittent fasting activates AMPK, which directly phosphorylates the V‑ATPase subunit ATP6V0D1 to boost lysosomal acidification during sleep. This heightened acid load shifts the autophagic machinery from bulk degradation to a ubiquitin‑dependent selective mode that tags synaptic proteins (e.g., PSD‑95, Synapsin‑1) for removal only when they are marked with K63‑linked ubiquitin chains accumulated during wakefulness. Consequently, sleep becomes an active editing step where the brain decides which synaptic architectures persist based on their ubiquitination state, and fasting sets the proteolytic threshold for this decision.

Mechanistic Basis

• AMPK‑V‑ATPase link: AMPK activation by fasting phosphorylates ATP6V0D1, increasing V‑ATPase assembly and proton pumping into lysosomes (4). Acidic lysosomes enhance cathepsin activity, favoring cleavage of ubiquitin‑linked substrates over long‑lived organelles.
• Ubiquitin code readout: During wakefulness, synaptic activity drives K63‑linked ubiquitination of postsynaptic scaffolds (5). Acidic lysosomes possess ubiquitin‑binding adaptors (e.g., p62/SQSTM1) that exhibit higher affinity for K63 chains at low pH, coupling synaptic tagging to autophagic capture.
• Glymphatic‑astrocyte coupling: Low norepinephrine during slow‑wave sleep expands interstitial space, boosting CSF influx (1, 3). Astrocytic AQP4 c

Hypothesis

Transient OSK expression followed by NAD+ replenishment during the post‑expression recovery phase will extend and stabilize the epigenetic youthfulness induced by partial reprogramming beyond the 4‑week window observed with OSK alone, without compromising cellular identity or increasing tumorigenic risk.

Rationale

1. OSK‑driven demethylation is TET‑dependent – OSK pulses activate TET1/2, leading to active DNA demethylation at aging‑altered loci [3]. TET enzymes require α‑ketoglutarate (α‑KG) as a co‑substrate and are inhibited by succinate and fumarate, metabolites that rise when NAD⁺ is low.
2. NAD⁺ fuels both sirtuins and TET activity – Elevated NAD⁺ increases α‑KG production via enhanced TCA cycle flux and activates SIRT1, which deacetylates and stabilizes TET2 [4]. NAD⁺ also supports PARP‑mediated DNA repair, reducing oxidative stress that can impede demethylation.
3. Recovery phase is a permissive window – After OSK withdrawal, cells undergo a chromatin remodeling phase where demethylation peaks and epigenetic age continues to decline [4]. Providing NAD⁺ during this window should amplify TET activity and lock in a youthful methylome.
4. Safety is preserved – OSK alone avoids pluripotency and teratoma formation [[2](https://rejuvenatebio.com/press-releases/rejuvenate-bio-announces-gene-therapy-mediated-partial-reprogramming-extends-lifespan-and-reverses-age-related-changes-in-the-journal-cellular-reprogrammi

Hypothesis

Acarbose extends lifespan preferentially in males by remodeling the gut microbiome to increase butyrate‑producing taxa, which activates the bile‑acid receptor TGR5 in intestinal epithelia and hepatocytes, thereby boosting the endocrine fibroblast growth factor 21 (FGF21) pathway. Male mice exhibit higher hepatic TGR5 signaling and androgen‑dependent upregulation of β‑Klotho, making them more responsive to butyrate‑driven FGF21 secretion, which promotes autophagy, insulin sensitivity, and stress resistance. Consequently, the male‑biased longevity effect of acarbose depends on microbiome‑derived butyrate acting through the TGR5‑FGF21 axis, independent of its glucose‑blunting activity.

Testable Predictions

1. Microbiota transfer: Germ‑free male mice receiving fecal microbiota from acarbose‑treated male donors will show increased fecal butyrate, hepatic TGR5 activation, elevated circulating FGF21, and extended median lifespan compared with recipients of female donor microbiota or vehicle controls.
2. Pharmacological blockade: Treating acarbose‑fed male mice with a TGR5 antagonist (e.g., SBI‑243) or intestinal‑specific Tgr5 knockout will abolish the lifespan extension and FGF21 rise without affecting post‑prandial glucose levels.
3. Sex‑specific signaling: Castrated males or females supplemented with testosterone will recapitulate the male‑level TGR5‑FGF21 response to acarbose‑induced microbiome shifts, linking androgen status to pathway sensitivity.
4. Glucose independence: Pair‑fed controls matched for reduced caloric intake due to acarbose wi

Hypothesis: In aged bone marrow, adipocyte-derived leptin activates the leptin receptor on erythroid progenitors, triggering JAK2-STAT3 signaling and upregulating SOCS3, which then blocks EPO-induced JAK2-STAT5 phosphorylation despite normal EPOR expression. This creates a functional EPO resistance that worsens anemia. Moreover, EPO-stimulated osteoclast activity raises RANKL and inflammatory cytokines (TNF-α, IL-6) that further stimulate adipocyte leptin production, forming a feed-forward loop that deepens the block.

It's known that aged marrow accumulates adipocytes, but the leptin-SOCS3 axis linking fat to erythroid signaling hasn't been directly tested.

Predictions

• Aged mice will show higher leptin receptor phosphorylation and SOCS3 protein in Ter119+CD71+ erythroid progenitors compared with young mice, and these levels will correlate positively with marrow adipocyte area and negatively with ex vivo EPO-stimulated pSTAT5.
• Conditional deletion of SOCS3 specifically in erythroid progenitors (using Gata1-Cre or EpoR-Cre) will restore EPO-induced pSTAT5, increase hemoglobin response to exogenous EPO, and reduce adipocyte expansion without altering osteoclast numbers.
• We expect that pharmacologic blockade of the leptin receptor (using a pegylated leptin antagonist) will mimic the genetic SOCS3 loss, lowering SOCS3 expression and improving EPO responsiveness.
• Inhibiting osteoclastogenesis (with anti-RANKL or os inhibitors) will lower marrow inflammation but won't rescue EPO-STAT5 signaling if SOCS3 remains intact, indicating that adipocyte leptin-SOCS3 is downst

Hypothesis

Emodin, by inhibiting EGFR/MAPK signaling, alters the phosphorylation state and adaptor function of p62/SQSTM1, shifting the hierarchical order of selective autophagy toward ubiquitinated anti‑apoptotic proteins (e.g., BCL‑2, BCL‑XL) in senescent cells. This reprogrammed cargo prioritization triggers senolysis without requiring bulk autophagy induction.

Mechanistic Rationale

• EGFR inhibition reduces downstream ERK activity, which has been shown to phosphorylate p62 at Ser403 and modulate its ubiquitin‑binding affinity [Emodin anti‑inflammatory action via EGFR inhibition]; altered phosphorylation can change p62’s preference for specific ubiquitin chain types or cargo adapters.
• In senescent cells, anti‑apoptotic BCL‑2 family members are often ubiquitinated and earmarked for selective autophagy [p62/SQSTM1 functions as a selective autophagy receptor]; a change in p62 selectivity could preferentially degrade these survival factors.
• Precedent exists for compounds that upregulate SQSTM1 and redirect autophagy to degrade specific inflammatory mediators [CpdA upregulates SQSTM1 and induces autophagy]; emodin may act similarly but via EGFR‑dependent signaling rather than direct transcriptional upregulation.
• Disrupting the normal hierarchy of autophagy—where damaged mitochondria are cleared first—could lead to accumulation of deleterious organelles, thereby lowering the threshold for apoptosis when anti‑apoptot

Hypothesis

The 265 super‑central proteins identified in the human aging interactome act as a nucleolar‑centric hub that couples ribosome biogenesis to ubiquitin‑mediated quality control. When these hub proteins become dysregulated with age, they trigger nucleolar stress, causing the release of nuclear alarmins (e.g., IL‑1α, HMGB1) that act as cytokines to coordinate a body‑wide proteostatic decline. This mechanism explains why nucleolar ribosome biogenesis disorganization precedes other hallmarks, why nearly half of age‑changes are sex‑specific (female‑biased immune activation), and why targeting canonical longevity proteins like mTOR yields inconsistent lifespan effects.

Key predictions

1. Selective knockdown or CRISPR‑mediated reduction of individual hub proteins in mouse liver and brain will increase nucleolar stress markers (e.g., nucleolar enlargement, reduced pre‑rRNA) and elevate circulating alarmin cytokines within 2 weeks.
2. The cytokine surge will precede detectable declines in proteostasis reporters (e.g., ↑ ubiquitinated proteins, ↓ HSP70) in distal tissues such as spleen and skin.
3. Female mice will show a larger cytokine response and faster proteostasis collapse than males, mirroring the observed broader immune activation.
4. Rescue of nucleolar integrity by overexpressing a nucleolar chaperone (e.g., nucleophosmin) or neutralizing the released cytokine (anti‑IL‑1α antibody) will restore proteostasis and extend median lifespan, whereas similar interventions in males will produce a smaller effect.
5. In human induced pluripotent stem cell‑derived org

Hypothesis

Matching newly synthesized ETC capacity with a precisely tuned matrix NAD+/NADH ratio improves supercomplex stoichiometry, reduces reverse electron transport–derived ROS, and enhances oxidative phosphorylation efficiency beyond what either intervention achieves alone.

Mechanistic rationale

PGC-1α–driven transcription expands mitochondrial mass and ETC subunit expression (1), but nascent complexes require proper NADH/FADH2 balancing for stable supercomplex assembly (3). When matrix NAD+/NADH falls below ~7–8, excess NADH drives reverse electron transport at Complex I, a major ROS source (4). Mitochondrial‑targeted LbNOX raises the matrix NAD+/NADH ratio without altering proton pumping, alleviating reductive stress and rescuing ETC defects (5,6). We propose that simultaneous activation of PGC-1α (e.g., via β3‑adrenergic signaling or AMPK/PKA phosphorylation) and matrix‑restricted NAD+ elevation creates a feedback loop: new ETC subunits are incorporated into supercomplexes only when the redox environment favors forward electron flow, thereby preventing the accumulation of unassembled or misassembled intermediates that generate ROS.

Testable predictions

1. Cells treated with a PGC-1α activator (e.g., ZLN005) plus mitochondri

Hypothesis

Claim: A moderate‑duration cold water immersion (CWI) protocol (10–15 min at 5–10 °C) produces a sustained norepinephrine (NE) elevation that activates β3‑adrenergic receptors on skeletal muscle, driving a cAMP‑PKA‑CREB‑PGC‑1α signaling cascade that promotes mitochondrial biogenesis and improves resistance‑training adaptations. In contrast, an extreme‑brief exposure (≈3 min at 1 °C) generates a sharp, transient NE spike insufficient to maintain downstream signaling, leading to maladaptive stress responses (elevated cortisol, HSP70 without concomitant PGC‑1α up‑regulation).

Mechanistic rationale

1. NE kinetics – Human studies show plasma NE peaks within 1–2 min of cold onset and remains elevated for the duration of exposure when core temperature falls gradually (see meta‑analysis of medium‑duration protocols)[1]. A 3‑min plunge at 1 °C triggers a rapid peak but rapid return to baseline due to abrupt vasoconstriction and limited afferent feedback.
2. β3‑adrenergic coupling – Skeletal muscle expresses β3‑ARs that, when stimulated by NE, increase intracellular cAMP via Gs proteins. Sustained cAMP activates protein kinase A (PKA), which phosphorylates CREB at Ser133, promoting transcription of PGC‑1α and downstream oxidative‑phosphorylation genes.[2]
3. FGF21 amplification – Cold‑induced NE also stimulates hepatic FGF21 release; FGF21 can act in an autocrine‑paracrine loop on muscle to further enhance PGC‑1α expression and fatty‑acid oxidation.[3]
4. Threshold hypothesis – The adaptive cascade requires NE exposure above a concentration‑ti

Hypothesis

Combined pharmacological NLRP3 inhibition (e.g., MCC950), IL-6 receptor blockade (e.g., anti‑IL‑6R antibody), and periodic senolytic clearance (e.g., dasatinib + quercetin) will reverse age‑associated immunosenescence in humans by reducing inflammasome‑driven oxidative stress in hematopoietic stem cells (HSCs), thereby restoring youthful DNA methylation patterns and lymphoid‑myeloid balance.

Mechanistic Rationale

NLRP3 activation in aged macrophages and perivascular adipose tissue releases caspase‑1‑processed IL-1β and IL-18, which augment mitochondrial ROS production in neighboring HSCs [1][3]. Elevated ROS drives DNMT3A‑mediated hypermethylation at promoters of lymphoid‑specification genes (e.g., IKZF1, EBF1), biasing hematopoiesis toward myeloid output and exacerbating inflammaging [4]. IL-6, while not a direct NLRP3 product, amplifies STAT3 signaling that further stabilizes the senescent phenotype in macrophages and impairs HSC niche support [2]. Senolytics eliminate NLRP3‑primed senescent immune cells, decreasing the chronic cytokine milieu that sustains HSC stress [5]. Simultaneous NLRP3 blockade cuts the upstream ROS source, IL-6 inhibition dampens the downstream amplifier, and senolytic removal reduces the cellular source of inflammasome activators, together normalizing the oxidative‑epigenet

Hypothesis

Integrating transformer-based feature learning with Bayesian uncertainty quantification and time-varying effect modeling yields a survival model (BT-TVEM) that significantly outperforms current benchmarks for disability-free survival and identifies epigenetically driven, age‑dependent pathways of frailty.

Model Architecture

• Transformer Encoder: Processes raw DNA‑methylation β‑values (or proteomic intensities) across CpG sites, learning non‑linear interactions and producing a latent representation Z.
• Attention‑Weighted Pathway Mapping: The self‑attention matrices are aggregated to assign importance scores to each CpG; these scores are projected onto curated pathway databases (e.g., KEGG, Reactome) to generate a dynamic pathway activity vector P(t) that varies with age.
• Bayesian Survival Layer: A Cox‑type hazard function λ(t|Z,P) = λ₀(t) exp(βᵀZ + γ(t)ᵀP) where β are fixed effects and γ(t) are time‑varying coefficients modeled via Bayesian penalized splines, providing posterior predictive distributions for individual hazards.
• Training Objective: Maximize the marginal likelihood of observed survival times while regularizing attention sparsity and spline smoothness.

Testable Predictions

1. Predictive Performance: In the Framingham Heart Study offspring cohort (n≈3,000, 12‑year follow‑up), BT-TVEM will achieve a concordance index (C‑index) ≥0.86 for disability‑free survival, exceeding the Healthy Longevity Index (C‑index 0.79) and the TTSurv baseline (≈0.81) [3, [1](https://pmc.ncbi

Hypothesis

Circadian disruption increases epigenetic entropy at subtelomeric regions, accelerating telomere shortening independent of replication count. Melatonin, whose secretion is suppressed by light exposure, reduces this epigenetic noise and thereby preserves telomere length.

Mechanistic Rationale

• Telomere attrition is traditionally linked to mitotic history, yet data show strong associations with sleep quality, timing, and light-at-night that persist after controlling for total sleep duration [3, 4, 5, 6].
• Melatonin acts as a potent antioxidant and regulates chromatin remodeling enzymes (e.g., HDACs, HATs) that influence heterochromatin stability [7].
• We propose that melatonin’s primary anti‑aging action at telomeres is to limit the accumulation of epigenetic modifications—such as aberrant DNA methylation and histone variant deposition—that increase the informational entropy of subtelomeric chromatin. Higher entropy promotes a more open chromatin state, exposing telomeric DNA to oxidative damage and impairing shelterin complex binding, thus hastening shortening.

Testable Predictions

1. In vitro: Human fibroblasts exposed to constant light (to suppress melatonin) will show increased subtelomeric methy

Hypothesis

Repeated, low‑intensity activation of the nociceptor ion channel TRPV1 triggers a hormetic cascade that enhances cellular stress resistance and extends lifespan. This effect depends on calcium‑mediated activation of the CaMKK2‑AMPK‑SIRT1 signaling axis, leading to increased NAD+ levels, FOXO3 deacetylation, and upregulation of antioxidant and autophagy genes. Chronic analgesic use that suppresses TRPV1 activity abolishes this benefit, thereby accelerating age‑related decline.

Mechanistic Rationale

1. TRPV1‑mediated Ca²⁺ influx – Brief capsaicin or heat exposure raises intracellular calcium in peripheral nociceptors without inducing lasting injury.
2. CaMKK2 activation – Elevated Ca²⁺ binds calmodulin, activating CaMKK2, which phosphorylates and activates AMPK.
3. AMPK‑SIRT1 coupling – AMPK raises NAD+ via increased NAMPT expression and inhibits mTORC1, creating a permissive environment for SIRT1 deacetylase activity.
4. FOXO3 and NRF2 activation – SIRT1 deacetylates FOXO3, promoting its nuclear translocation and transcription of SOD2, CAT, and autophagy genes (e.g., LC3B). Concurrently, AMPK phosphorylates NRF2, enhancing its stability and antioxidant response element (ARE) driven gene expression.
5. Outcome – Improved mitochondrial biogenesis, reduced ROS accumulation, enhanced proteostasis, and lower senescent cell burden.

Testable Predictions

• In vivo – Mice receiving intermittent, low‑dose capsaicin (0.1 mg/kg, i.p., twice weekly) will show increased median lifespan (~10‑15 %) and reduced senescence‑associated β‑galactosida

Hypothesis

Senescent cardiac progenitor cells (CPCs) release mitochondrially‑derived DNA packaged in extracellular vesicles that activate the cGAS‑STING pathway in neighboring CD45⁻/c‑Kit⁺ progenitors, converting IGF‑1Rlow cells into a senescent state and amplifying the regenerative deficit in the aged heart.

Rationale

Aged hearts accumulate dysfunctional CPCs marked by p16^INK4A^, SA‑β‑gal, γH2AX and telomere attrition, which limits replication and differentiation [1]. These senescent CPCs secrete a SASP that induces paracrine senescence in adjacent cells [1]. Mitochondrial DNA integrity is required for CPC function, and age‑related mtDNA mutations impair proliferation [3]. Circulating cell‑free mtDNA (cf‑mt‑DNA) released from damaged cells can trigger innate immune sensors such as cGAS, leading to STING‑dependent IFN‑β production and senescence [4]. Moreover, only the CD45⁻/c‑Kit⁺ subpopulation exhibits robust clonogenic and myogenic capacity, while bulk c‑Kit⁺ cells are endothelial‑committed and poorly regenerative [2]. IGF‑1R marks a subset of human cardiac stem cells with superior therapeutic potential, yet its expression declines with age [5]. We propose that senescent CPCs selectively package damaged mtDNA into exosomes that are taken up by IGF‑1Rlow CD45⁻/c‑Kit⁺ progenitors, where mtDNA engages cGAS, activating STING and driving a senescent phenotype that suppresses IGF‑1R signaling and regenerative output.

Testable Predictions

1. Isolates of extracellular vesicles from senescent CPCs will contain elevate

Aging cells actively suppress autophagy by locking autophagy gene promoters in a repressive chromatin state through a metabolite‑sensitive lncRNA that recruits PRC2.

The age‑associated drop in SLC1A5‑mediated glutamine import lowers intracellular α‑ketoglutarate (α‑KG) levels. α‑KG is a required cofactor for α‑KG‑dependent dioxygenases such as the m6A demethylases ALKBH5 and FTO, which normally destabilize certain nuclear lncRNAs by promoting their degradation. When α‑KG falls, these dioxygenases become less active, leading to the stabilization of lncRNAs that can guide Polycomb Repressive Complex 2 (PRC2) to chromatin. One candidate, MALAT1, is known to interact with EZH2 and to be regulated by m6A methylation; its stability increases when α‑KG‑dependent demethylases are inhibited.

Testable hypothesis: In aged cells, reduced α‑KG stabilizes MALAT1, which then recruits EZH2 to autophagy gene promoters (e.g., TFEB, ULK1, BECN1, ATG7, LC3B), increasing H3K27me3 and silencing transcription. Restoring autophagy flux should be possible by destabilizing MALAT1 or blocking its interaction with EZH2, even without correcting SLC1A5 loss.

Experimental plan:

• Measure SLC1A5 expression, intracellular α‑KG, and MALAT1 levels in young versus aged murine hematopoietic stem cells or skeletal muscle.
• Perform RNA immunoprecipitation (RIP) for EZH2 to quantify MALAT1‑EZH2 binding in both age groups.
• Use CUT&Tag to map H3K27me3 at autophagy gene promoters; predict higher enrichment in aged cells that correlates with MALAT1‑EZH2 occupancy.
• Knockdown MALAT1 with siRNA or antise

Hypothesis

Transient inhibition of the histone methyltransferases SUV39H1/2 before OSKM expression lowers H3K9me3 at pericentromeric and telomeric heterochromatin, thereby increasing accessibility for reprogramming factors and decreasing the persistent methylation scars that survive iPSC generation.

Mechanistic Rationale

’s data show that incomplete reprogramming leaves megabase‑scale methylation errors concentrated at pericentromeric and telomeric regions (2). These same regions are enriched for H3K9me3, a mark that compacts chromatin and impedes transcription factor binding (6). Age‑associated cells accumulate higher levels of H3K9me3 at these loci, correlating with the observed inverse relationship between donor cell methylation load and reprogramming efficiency (1). By pharmacologically reducing SUV39H1/2 activity, we predict a local relaxation of heterochromatin, allowing OCT4, SOX2, KLF4 and c‑MYC to engage their target sites more efficiently, leading to more complete erasure of both CG and non‑CG methylation and a diminished epigenetic memory bias upon redifferentiation.

Experimental Design

1. Cell preparation – Obtain fibroblasts from young (≤20 yr) and old (>60 yr) donors. Split each line into three groups: untreated control, 24‑hour treatment with the SUV39H1/2 inhibitor chaetocin (0.5 µM), and vehicle control (DMSO).
2. Reprogramming – After inhibitor washout, induce iPSC formation using a

Hypothesis

Co-transplanting iPSC-derived dopaminergic neurons (DA) with iPSC-derived microglia-like cells (iMG) will improve functional integration and behavioral recovery in Parkinsonian rodents by supplying activity-dependent BDNF and modulating the inflammatory milieu.

Rationale

• Preclinical work shows iPSC-DA grafts survive variably and often fail to form robust circuits [2]
• iPSC-derived microglia can phagocytose debris and release neurotrophic factors, including BDNF, in response to neuronal activity [3]
• BDNF signaling promotes dopaminergic neuron maturation, axon outgrowth, and synaptic plasticity, which are critical for circuit restoration.
• Allogeneic off-the-shelf iPSC lines are now in clinical trials, indicating manufacturing scalability [1]

Experimental Design

1. Groups (n=10 per group):
   • Vehicle control
   • DA neurons alone
   • DA + iMG (1:1 ratio)
   • DA + iMG + BDNF neutralizing antibody
   • DA + iMG + P2X7 receptor antagonist (to block activity-dependent BDNF release)

Hypothesis: Age-related pathological hypermineralization of bone matrix alters osteocyte signaling, reducing the release of carboxylated osteocalcin and increasing sclerostin, which together dampen hippocampal neurogenesis and cortical plasticity, manifesting as cognitive rigidity. Restoring normal osteocyte mechanosensing through intermittent low-magnitude vibration will decrease pathological mineralization, normalize osteocalcin carboxylation, and improve cognitive flexibility in aged mammals.

Mechanistic

rationale: In aging bone, hydroxyapatite crystals enlarge and infiltrate osteocyte lacunae and canaliculi, creating a stiff, brittle matrix that impairs fluid shear stress detection by osteocytes [2]. This mechanotransduction deficit lowers intracellular calcium oscillations, leading to reduced transcriptional activity of RUNX2 and decreased vitamin K-dependent gamma-carboxylation of osteocalcin [3][4]. Undercarboxylated osteocalcin accumulates systemically, but its inability to bind hydroxyapatite fails to restrain crystal growth, perpetuating a vicious cycle of hypermineralization. Simultaneously, mechanosensitive osteocytes increase sclerostin secretion, which antagonizes Wnt/beta‑catenin signaling in neural progenitor cells, suppressing hippocampal neurogenesis [5]. The net effect is a brain environment that favors stable, over‑consolidated neural networks—mirroring the seed idea that aging reflects excessive prediction certainty rather than simple decay.

Testable predictions: 1) Aged mice exhibiting elevated lacunar mineralization (quantified by synch

Hypothesis

Aging‑induced intestinal epithelial senescence secretes a glucocorticoid‑rich SASP that directly upregulates ileal ASBT (SLC10A2) via SGK1, creating a feed‑forward loop that traps conjugated primary bile acids in the enterohepatic circulation, elevates serum and brain bile acid levels, and drives cognitive impairment.

Mechanistic Rationale

1. Senescence‑derived glucocorticoids – Senescent intestinal epithelial cells increase local cortisol/corticosteroid production (or activate glucocorticoid receptor signaling) as part of the SASP, mirroring the hepatic steatosis model where senescence‑SASP drives metabolic dysfunction 4.
2. SGK1 activation – Glucocorticoid‑bound receptor induces SGK1 transcription, which phosphorylates and stabilizes ASBT at the apical membrane, enhancing reabsorption of conjugated primary bile acids (CPBAs) 1.
3. Disrupted FXR‑FGF15 feedback – Age‑related dysbiosis reduces bile‑salt‑hydrolase activity, preserving CPBAs in the lumen and sustaining FXR activation; however, the heightened ASBT activity overwhelms the feedback, leading to net hepatic BA synthesis suppression (CYP7A1 down) 1 3.
4. Spillover to circulation – Excess CPBA reabsorption raises portal and systemic bile acid concentrations, facilitating blood‑brain barrier transport and accumulation in hippocampal neurons, where they perturb synaptic plasticity and pr